Skip to Main Content

Paper Details

A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer.
Invest New Drugs
13
2019
Author NameAffiliation
Mario A EisenbergerJohns Hopkins University
Elisabeth I HeathKarmanos Cancer Institute, Wayne State University
Dana E RathkopfMemorial Sloan Kettering Cancer Center
Dana E RathkopfWeill Cornell Medical College
Emmanuel S AntonarakisJohns Hopkins University
Michael J MorrisMemorial Sloan Kettering Cancer Center
Michael J MorrisWeill Cornell Medical College
  • 1 - 7

Datasets

Release 1.2